PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24577942-0	2014	Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.	AZD 1480	56-63	interleukin 6	Mus musculus	82-86	
24577942-8	2014	Most importantly, pharmacologic inhibition of Jak1/2 by AZD1480 suppressed IL-6-induced signaling, migratory prostate cancer cell phenotypes, and metastatic dissemination of prostate cancer in vivo in nude mice.	AZD 1480	56-63	interleukin 6	Mus musculus	75-79	
24577942-9	2014	In conclusion, we demonstrate that the cytokine IL-6 directly promotes prostate cancer metastasis in vitro and in vivo via Jak-Stat3 signaling pathway, and that IL-6-driven metastasis can be effectively suppressed by pharmacologic targeting of Jak1/2 using Jak1/2 inhibitor AZD1480.	AZD 1480	274-281	interleukin 6	Mus musculus	48-52	
24577942-9	2014	In conclusion, we demonstrate that the cytokine IL-6 directly promotes prostate cancer metastasis in vitro and in vivo via Jak-Stat3 signaling pathway, and that IL-6-driven metastasis can be effectively suppressed by pharmacologic targeting of Jak1/2 using Jak1/2 inhibitor AZD1480.	AZD 1480	274-281	interleukin 6	Mus musculus	161-165	
23531921-5	2013	Our data indicate that AZD1480 blocks endogenous as well as IL-6 induced STAT3 activation.	AZD 1480	23-30	interleukin 6	Mus musculus	60-64